Journal of Psychopharmacology

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

SAGETRACK

Sign In to gain access to subscriptions and/or personal tools.
This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
0269881106068289v1
21/4/453    most recent
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Karunakaran, K.
Right arrow Articles by Harborne, G. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Karunakaran, K.
Right arrow Articles by Harborne, G. C.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?
This version was published on June 1, 2007
Journal of Psychopharmacology, Vol. 21, No. 4, 453-456 (2007)
DOI: 10.1177/0269881106068289

Is clozapine—aripiprazole combination a useful regime in the management of treatment-resistant schizophrenia?

Kanapathippillai Karunakaran

North East Wales NHS Trust, Wrexham Maelor Hospital, Croesnewydd Road, Wrexham, UK

Tongeji E. Tungaraza

North East Wales NHS Trust, Pwll Glas Resources Centre, Pwll Glas Road, Mold, Flintshire, UK, eliphaz{at}doctors.org.uk

Giles C. Harborne

North East Wales NHS Trust, Wrexham Maelor Hospital, Croesnewydd Road, Wrexham, UK

Around 40—70% patients with treatment-resistant schizophrenia fail to respond to clozapine. Though combining antipsychotics is commonly practised with non-responders, there is Little evidence for its use.

We carried out a retrospective review of case notes of patients with treatment-resistant schizophrenia on clozapine—aripiprazole combination at our clozapine clinic. We report changes in psychotic symptoms, social function, weight, total cholesterol, serum glucose, HDL, CGI and GAF score pre- and post-aripiprazole augmentation.

Clozapine—aripiprazole combination was associated with 22% reduction of clozapine dose. Eighteen out of 24 (75%) Lost a mean weight of 5.05 kg. There was improvement in positive and negative symptoms, sociaL functions, weight Loss and a moderate increase in HDL. Our findings suggest that clozapine—aripiprazole is a safe and tolerable combination; however, controL trials are needed to validate our findings.

Key Words: treatment resistant • schizophrenia • clozapine • aripiprazole • augmentation • weight


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 J PsychopharmacolHome page
U. Lang, M. Willbring, R. von Golitschek, A. Schmeisser, K. Matschke, and S M. Tugtekin
Clozapine-induced myocarditis after long-term treatment: case presentation and clinical perspectives
J Psychopharmacol, July 1, 2008; 22(5): 576 - 580.
[Abstract] [PDF]

Home page
 Schizophr BullHome page
C. U. Correll, C. Rummel-Kluge, C. Corves, J. M. Kane, and S. Leucht
Antipsychotic Combinations vs Monotherapy in Schizophrenia: A Meta-analysis of Randomized Controlled Trials
Schizophr Bull, April 21, 2008; (2008) sbn018v2.
[Abstract] [Full Text] [PDF]